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AbstrACt
Introduction Chronic kidney disease (CKD) affects up to 
16% of adults in the UK. Patient quality of life is particularly 
reduced in end-stage renal disease and is strongly 
associated with increased hospitalisation and mortality. 
Thus, accurate and responsive healthcare is a key priority. 
Electronic patient-reported outcome measures (ePROMs) 
are online questionnaires which ask patients to self-rate 
their health status. Evidence in oncology suggests that the 
use of ePROM data within routine care, alongside clinical 
information, may enhance symptom management and 
improve patient outcomes. However, National Health Service 
(NHS)-based ePROM research in CKD is lacking. This pilot 
trial will assess the feasibility of undertaking a full-scale 
randomised controlled trial (RCT) in patients with CKD within 
the NHS.
Methods and analysis The renal ePROM pilot trial is 
an investigator-led single-centre, open-label, two-arm 
randomised controlled pilot trial of 66 participants ≥18 
years with advanced CKD. Participants will be randomised 
to receive either usual care or usual care supplemented 
with an ePROM intervention. Participants within the 
intervention arm will be asked to submit monthly self-
reports of their health status using the ePROM system. 
The system will provide tailored information to patients 
in response to each report and notify the clinical team of 
patient deterioration. The renal clinical team will monitor 
for ePROM notifications and will respond with appropriate 
action, in line with standard clinical practice. Measures 
of study feasibility, participant quality of life and CKD 
severity will be completed at 3 monthly intervals. Health 
economic outcomes will be assessed. Clinicians will record 
treatment decision-making. Acceptability and feasibility of 
the protocol will be assessed alongside outcome measure 
and intervention compliance rates. Qualitative process 
evaluation will be conducted.
Ethics and dissemination The findings will inform the 
design of a full-scale RCT and the results will be submitted 
for publication in peer-reviewed journals. The study has 
ethical approval.
trial registration numbers ISRCTN12669006; Pre-
results.
IntroduCtIon
Chronic kidney disease (CKD) affects up to 
16% of adults in the UK,1 with an annual 
estimated cost of £1.45 billion.2 More than 
half of these costs were associated with renal 
replacement therapy (RRT)—haemodialysis, 
peritoneal dialysis and/or kidney transplan-
tation—for patients with end-stage renal 
disease (ESRD).2 This is despite the fact that 
patients requiring RRT comprise less than 
1% of the total CKD population.2 Numerous 
studies have demonstrated that patients with 
ESRD experience high symptom burden and 
a very high prevalence of depression.3 More-
over, patient quality of life is significantly 
reduced in ESRD and is strongly associated 
with increased hospitalisation and mortality.3 
Accurate and responsive healthcare for 
patients as they progress from advanced CKD 
to ESRD is therefore a key healthcare priority.
Effective management of advanced CKD 
relies on the timely detection of clinical dete-
rioration towards ESRD. This can be a major 
challenge between scheduled clinic visits, 
strengths and limitations of this study
 ► The study uses a randomised controlled trial  (RCT) 
design, delivered in a National Health Service (NHS) 
setting.
 ► The research site, University Hospitals Birmingham 
NHS Foundation Trust, hosts one of the largest spe-
cialist renal research sites in Europe.
 ► The study protocol and intervention was developed 
by a multidisciplinary team of experts including: pa-
tients, healthcare professionals and academics.
 ► As a pilot trial, the study is limited to one clinical 
centre and is not statistically powered to assess 
clinical outcomes. Instead, the project will evaluate 
feasibility of conducting a full-scale RCT in the tar-
get population.
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when it is often difficult to identify clinical deterioration 
unless a patient self-refers. Unfortunately, some patients 
self-refer too late because they have difficulty identifying 
the point at which they may require assistance. Without 
prompt recognition of advanced symptoms, such patients 
are at high risk of severe illness, emergency hospitalisa-
tion and associated worse clinical outcomes.3
Patient-reported outcome measures (PROMs) are vali-
dated questionnaires which ask patients to self-rate their 
health status. They can provide important information 
regarding the patient’s perspective on the physical, func-
tional and psychological consequences of treatment and 
the degree and impact of disease symptoms.4 Evidence 
suggests that the use of PROM data, alongside regular 
clinical information, within routine care may:
 ► Aid patient–provider communication and support 
shared decision-making.5
 ► Improve patient activation and help patients to feel 
more involved/empowered in decisions around their 
care.6–8
 ► Improve the accuracy of symptom assessment and 
enhance symptom management.9
 ► Enhance patient education and self-management and 
maximise patient safety.7 10–15
With recent advances in technology, there has been 
considerable interest in the use of electronic PROMs 
(ePROMs) for the routine monitoring of patients with 
long-term conditions. ePROMs offer patients an ‘elec-
tronic’ method of data entry—for example, web based via 
PC, smartphone or using tablet devices—and give clini-
cians a flexible platform with which they may view PROM 
data.14 16 17
ePROMs offer patients the option of inputting data 
at a time and place, and via a platform, that is conve-
nient to them. ePROM data can be used to help provide 
patients with tailored advice on self-management and 
can provide clinicians with detailed health-related quality 
of life (HRQL) and symptom data both in clinic and 
between scheduled appointments via home/remote data 
capture.15
For patients with advanced CKD, this would allow clini-
cians to monitor for symptom deterioration, facilitating 
the early detection of problems requiring attention and 
promoting timely intervention from the clinical team (eg, 
advice aimed at aiding patient self-management or escala-
tion of care). Such intervention may delay disease progres-
sion and the need for costly and invasive RRT, and reduce 
emergency hospitalisations and other adverse outcomes.
A recent randomised controlled trial (RCT) conducted 
in an oncology setting in the USA, demonstrated that 
ePROM use is associated with improved HRQL, reduced 
accident and emergency visits, reduced hospitalisations 
and superior quality-adjusted survival.15 Both in Canada 
and Denmark, ePROM collection has been shown to be 
feasible in a renal population.16 18 19 However, National 
Health Service (NHS)-based ePROM research in CKD, 
utilising real-time patient and clinician feedback is 
lacking. Routine remote use of ePROM data by patients 
with advanced CKD may aid self-management, while also 
helping to improve the flow of information between 
patients and their clinicians, potentially improving 
patient safety, enhancing clinical interactions, optimising 
patient outcomes and delivering cost savings to the NHS.
A RCT is needed to evaluate ePROM efficacy in 
advanced CKD to determine if health professionals, 
providers and policy-makers should implement routine 
ePROM collection in renal practice. However, before a 
definitive trial is undertaken, a pilot trial is required to 
assess the feasibility of undertaking such a study and to 
help inform the key elements (eg, appropriate outcome 
measure, sample size) of the design for the full-scale RCT.
MEthods
design
The renal ePROM (RePROM) study will span two phases: 
stage 1 involves development of the ePROM intervention 
with patient and clinician input; stage 2 is a pilot/feasi-
bility RCT with a qualitative substudy.
setting
Patients under the care of the renal services at Queen Eliz-
abeth Hospital Birmingham (QEHB) will be recruited for 
this study.
Stage 1: intervention development
Design of the ePROM system will be finalised during 
a series of operational meetings, held in stage 1 of the 
study, with regular input from: (1) the QEHB renal clin-
ical and research team; (2) the RePROM patient advi-
sory group (PAG); (3) the QEHB IT and Informatics 
group; (4) the University of Birmingham Clinical Trials 
Unit (BCTU) and (5) the Patient CentredOutcomes 
Group at the University of Leeds.
The ePROM system will be made available to study 
participants via ‘myHealth@QEHB’, a secure patient 
portal linked to the patient’s electronic healthcare 
record (EHR), delivered by the host site. The system will 
be developed to allow patients to self-report their health 
status using a variety of electronic platforms, for example, 
PC, smartphone or tablet.
The ePROM system will be designed to: (1) provide 
appropriate self-management advice to participants whose 
questionnaire scores suggest mild/moderate symptoms 
and (2) notify the clinical team of patient deterioration 
via an automated email, where the patient’s questionnaire 
responses indicate severe symptoms/cause for concern.
Patients’ longitudinal ePROM scores will be made avail-
able to clinicians for use during routine outpatient consul-
tations via the EHR. The RePROM PAG felt this approach 
would help to focus clinical discussion on patient-centred 
issues and may enhance symptom management, a view 
supported by related literature.7 8 16 17 20–22
Stage 2: pilot/feasibility RCT and qualitative substudy
Trial design
The RePROM pilot trial is an investigator led single-
centre, open-label, two-arm randomised controlled pilot 
 o
n
 8 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026080 on 28 October 2018. Downloaded from 
3Kyte D, et al. BMJ Open 2018;8:e026080. doi:10.1136/bmjopen-2018-026080
Open access
trial of 66 participants aged 18 years or over with advanced 
CKD. Participants will be randomised to receive either 
usual care or usual care supplemented with an ePROM 
intervention. The study flow is outlined in figure 1.
recruitment and eligibility
Recruitment is scheduled to commence in July 2018. 
Patients will be invited to participate based on the 
following eligibility criteria:
Inclusion criteria
 ► Aged ≥18 years old.
 ► Ability to provide fully informed written consent for 
participation in the study.
 ► Patients under the care of the renal services at QEHB.
 ► Patients meeting the trial definition of advanced CKD:
 – An estimated Glomerular filtration rate (eGFR) 
≥6 and ≤15 mL/min/1.73 m2 (inclusive).
 – OR
 – A projected risk of progression to end-stage renal 
failure within 2 years ≥20% using the 4-variable 
Tangri renal risk calculator.23
Exclusion criteria
 ► Patients unwilling to use the ePROM intervention.
 ► Patients who, in the opinion of the consenting profes-
sional, cannot speak, read or write English sufficiently 
well to complete the ePROM unaided.
 ► An episode of acute kidney injury (defined in 
accordance with national guidelines) within the last 
3 months.24
 ► Patients meeting the trial definition of ESRD:
 – Currently receiving dialysis or scheduled to start in 
the next 2 weeks.
 – Has received (or has a scheduled date to receive) a 
kidney transplant.
 – eGFR ≤5 mL/min/1.73 m2.
 ► A terminal illness that, in the opinion of the consultant 
assessing eligibility, is likely to lead to the death of the 
patient within 6 months of starting participation in 
the study.
Patients fulfilling the entry criteria will have their eligi-
bility assessed by qualified personnel at the host research 
site with access to/full understanding of their medical 
history. All patients approached will be given a copy of 
the participant information sheet (PIS). Usually, this will 
be sent to the patient in the post, along with an invitation 
letter, normally in advance of their next clinic assessment. 
The renal research team may also contact the patient 
by phone at the time of sending out the PIS. Staff will 
allow time for potential participants to consider the infor-
mation provided, discuss the trial with their family and 
friends, and decide whether to take part. Alternatively, if 
deemed appropriate by the recruiting renal research team 
member, the PIS and invitation letter may be provided 
directly in clinic. Provided the patient feels they have had 
sufficient time to consider their potential involvement, 
consent may be sought at this same appointment.
Investigators/delegate(s) will ensure that they 
adequately explain the aim, trial intervention, anticipated 
benefits and potential hazards of taking part in the trial to 
the participant. They will also stress that participation is 
voluntary and that the participant is free to refuse to take 
Figure 1 RePROM trial schema. CKD, chronic kidney disease; QEHB, Queen Elizabeth Hospital Birmingham. 
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part and may withdraw from the trial at any time. The 
participant will be given the opportunity to ask questions. 
If the participant expresses an interest in participating 
in the trial, they will be asked to sign and date the latest 
version of the informed consent form (ICF).
trial intervention
Participants in the control arm will continue to receive 
usual care. Participants randomised to the intervention 
arm will be asked to commence monthly self-reporting 
of their health status using the ePROM system, after 
receiving a face-to-face training session.
Participants will receive automated reminders prior to 
each scheduled self-report and 24 hours after a failure 
to report if necessary, these will be delivered via a secure 
myHealth QEHB patient portal email or text message, 
according to participants’ preferences. Participants may 
also upload additional ad hoc reports to the system, if 
they feel this is necessary (eg, if they wish to communicate 
a sudden change in symptoms).
The ePROM system will provide tailored information 
to patients in response to each report (both scheduled 
and ad hoc) and alert the clinical team of patient deteri-
oration according to a priori determined alert threshold 
criteria established in the intervention development 
stage. After receiving training during the study setup 
period, the renal clinical team will monitor for ePROM 
alerts and will respond with appropriate clinical action, in 
line with standard clinical practice.
randomisation
Participants will be randomised at the level of the indi-
vidual in a 1:1 ratio to either usual care (control arm) or 
usual care supplemented with an ePROM) system (exper-
imental arm). A minimisation algorithm will be used 
within the online randomisation system to ensure balance 
in the treatment allocation over the following variables:
 ► Risk progression (<40%, vs ≥40%, using the 4-variable 
Tangri renal risk calculator23).
 ► Self-reported computer experience (defined as: 
regular use of a computer or tablet or smartphone at 
least weekly vs less than weekly).
 ► Ethnicity (‘white’ vs ‘non-white’).
A ‘random element’ will be included in the minimi-
sation algorithm, so that each patient has a probability 
(unspecified here), of being randomised to the oppo-
site treatment that they would have otherwise received.
outcome measures and study procedures
Primary outcome
The primary aims of the study are to pilot the trial protocol 
and assess the feasibility of undertaking a full-scale RCT 
on the use of ePROMs in the management of advanced 
CKD. This will include assessment of both quantitative 
and qualitative data. The pilot study will:
 ► Test and pilot the trial protocol (including recruit-
ment and retention rates, data collection processes, 
data completeness and adherence to the ePROM 
intervention).
 ► Assess the willingness of clinicians to randomise 
participants into the trial.
 ► Assess the willingness of people with advanced CKD to 
be randomised into the trial.
 ► Assess the acceptability of the ePROM intervention;
 ► Explore the need for a non-web-based intervention 
platform for participants who are unable to use the 
ePROM.
 ► Inform selection of the most appropriate primary 
outcome measure for the full-scale RCT.
 ► Provide data to help estimate the sample size for the 
full-scale RCT.
 ► Provide a platform to develop and pilot the processes 
to capture costs and outcomes to inform the health 
economic evaluation for the full-scale RCT.
 ► Determine key participation criteria for centre 
involvement in the full-scale RCT.
Outcome data
This pilot trial is not powered to detect differences in 
outcome measures, but it provides the opportunity to 
ensure that there are no issues with completion of the 
outcome data and proposed outcome measures for the 
main RCT. The following outcome data will be collected:
 ► HRQL data, using the paper version of the EuroQol 
five dimension, five level, questionnaire (EQ-5D-5L). 
The EQ-5D-5L is a reliable/validated generic measure 
of health status/utility commonly used internationally 
in cost-effectiveness research.25
 ► Clinical data including: serum creatinine, calcium, 
phosphate, bicarbonate, albumin, eGFR, Albu-
min-to-creatinine ratio (ACR), blood pressure and for 
participants with diabetes: glucose and glycosylated 
haemoglobin (HbA1c).
 ► The following event data: progression to ESRD, 
contact with healthcare professionals in secondary 
care (outpatient clinics and accident and emergency), 
inpatient hospitalisation, death.
 ► Healthcare resource use data will be collected at each 
study visit.
All study staff/participants will be invited to complete a 
trial process questionnaire at the end of the study, which 
will evaluate aspects surrounding: data collection forms/
questionnaires; randomisation procedure; acceptability 
of the intervention; appropriateness of the frequency of 
ePROM reporting; alert thresholds and management.
study procedures
During the baseline visit, patients will have demographic 
details recorded including age, self-assigned ethnicity, 
educational status, residential postcode (to derive Index 
of Multiple Deprivation), self-reported computer experi-
ence and medical history.
Patient quality of life will be assessed using a paper 
version of the EQ-5D-5L questionnaire (not a routine 
test). This will be completed by the participant at baseline 
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and at 3, 6, 9 and 12 months postrandomisation (assess-
ment window ±3 weeks). This questionnaire may be 
posted out to participants prior to their scheduled clinic/
research visit, but research staff will be on hand in clinic 
to assist with completion where required. The EQ-5D-5L 
instrument is a reliable/validated generic measure of 
health status commonly used in CKD trials research.25
Clinical data will be collected at baseline and at 3, 6, 9 
and 12 months (assessment window ±3 weeks), including: 
serum creatinine, calcium, phosphate, bicarbonate, 
albumin, eGFR, ACR, blood pressure and for participants 
with diabetes: glucose and HbA1c. Since these measures 
are routinely collected for clinical monitoring, the results 
closest to the calculated visit due date will be used for 
trial data, rather than repeating tests which have already 
been performed. If a result is not available within the visit 
window, the test should be performed at the trial visit. 
Healthcare resource use will be collected at 3, 6, 9 and 12 
months (assessment window ±3 weeks).
All data will be extracted from the source records and 
entered onto a secure database maintained by the BCTU 
after each scheduled follow-up visit. The database will 
automatically capture ePROM notification data. Between 
clinic visits, patients will be managed in accordance with 
local practice.
sample size and justification
As this is a pilot trial, no formal sample size calculation 
has been performed. Following recommendations for 
pilot studies, 30 patients or more are typically required 
to obtain estimates of the parameters needed for sample 
size estimation.26 27 To allow for a 10% drop-out and loss 
to follow-up rate, this pilot trial will aim to recruit at least 
33 participants in each group, a total of 66 participants. 
This will also allow the recruitment and retention rates to 
be estimated with 95% CI maximum widths of 20% and 
25%, respectively.
Analysis of outcome measures
A separate Statistical Analysis Plan will be produced and 
will provide a more comprehensive description of the 
planned statistical analyses. A brief outline of these anal-
yses is given below.
The primary comparison groups will be composed of 
those randomised to usual care (control group) versus 
those randomised to usual care supplemented with the 
ePROM intervention (experimental group). In the first 
instance, all analyses will be based on the intention to 
treat principle, that is, all participants will be analysed in 
the treatment group to which they were randomised irre-
spective of compliance with the allocated treatment or 
other protocol deviation. The data analysis for this pilot 
trial will be descriptive and mainly focus on CI estimation, 
with no hypothesis testing performed.
Data will be explored to assess the key feasibility 
aspects of undertaking a full-scale RCT on the use of 
ePROMs in the management of advanced CKD. Dichot-
omous feasibility measures, such as the recruitment 
and retention rates, as well as data completeness, will 
be reported as numbers and percentages. Where appro-
priate, these values will be summarised across treatment 
groups.
Adherence with the ePROM intervention will be 
assessed by calculating the number and percentage of 
participants who complete the ePROM reports as sched-
uled. To be considered adherent, participants will need 
to have submitted their report within 72 hours of the 
scheduled time point. Incomplete submissions (ie, with 
some questions not answered) will be accepted for the 
purpose of measuring adherence. Ad hoc ePROM reports 
(ie, those completed outside the scheduled reporting 
periods) will not contribute to the assessment of adher-
ence, although we will assess the number of ePROM 
reports completed by each participant.
The pilot data will also help inform the selection of 
the most appropriate primary outcome measure for the 
main RCT and provide data to facilitate estimation of the 
sample size required for the main RCT. Outcome data 
on HRQL and clinical data are collected at 3, 6, 9 and 
12 months postrandomisation. Analysis methods will be 
chosen according to the data type of the outcome under 
investigation, in brief:
 ► Continuous endpoints (eg, quality of life): These data 
will be summarised using means and SDs, with differ-
ences in means with 95% CIs reported. Longitudinal 
plots of the data over time will also be constructed for 
visual presentation of the data.
 ► Categorical (dichotomous) endpoints (eg, hospi-
talisation rates): The number of participants and 
percentages experiencing the event will be summa-
rised between groups.
 ► Time-to-event endpoints (eg, time to ESRD, 
mortality): The numbers of participants and percent-
ages experiencing the event will be summarised over 
time between groups. Kaplan-Meier survival curves 
will be constructed for visual presentation of time-to-
event data.
Subgroup analyses
Descriptive reports of subgroup variables will be limited 
to the same variables used in the minimisation algo-
rithm. The availability and completeness of data for the 
subgroup variables will be summarised to assess their 
appropriateness as minimisation variables for the main 
trial, but no formal analysis will be undertaken.
Missing data and sensitivity analyses
Every attempt will be made to collect full follow-up 
data on all study participants; it is thus anticipated that 
missing data will be minimal. The assessment of missing 
data is an outcome measure of this pilot trial. If a suit-
able primary outcome is identified during the pilot 
trial, the level of missing data will form one compo-
nent of the assessment of feasibility for a future trial. As 
this is a pilot trial, no formal sensitivity analysis will be 
conducted.
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Planned interim analysis
As this is a pilot trial, there are no plans for under-
taking any interim analyses. However, the trial steering 
committee (TSC) will have access to recruitment, reten-
tion and data collection information.
Planned final analyses
The primary analysis for the trial will occur once all 
participants have completed the 12-month assessment 
and corresponding outcome data has been entered onto 
the trial database, validated as being ready for analysis 
and the database locked. This analysis will include data 
items up to and including the 12-month assessment.
health economics
In this study, we will develop and pilot methods to capture 
the costs and outcomes to inform an economic evaluation 
in the main RCT. This will examine healthcare resource 
use and outcomes across the two arms of the study.
The primary perspective adopted will be NHS/personal 
social care; which will focus on healthcare resource use 
and costs including: renal staff activity in response to 
ePROM notifications; GP and hospital consultations; 
in-patient hospitalisation; medications; referrals and NHS 
costs associated with maintenance of the ePROM system.
Where possible, data on NHS resource utilisation will 
be collected from the electronic patient records. Other 
data will be collected via case report forms (CRFs), either 
completed in study follow-up visits or on event-triggered 
forms (eg, generated in response to an ePROM alert). 
Resource use will be valued using appropriate unit costs 
such as the British National Formulary and the most 
recent version of Unit Costs of Health and Social Care 
and NHS Reference Costs.28
Monitoring
Management and oversight
The Trial Management Group will monitor all aspects 
of the conduct and progress of the trial, ensure that the 
protocol is adhered to and take appropriate action to 
safeguard participants and the quality of the trial itself.
A single TSC will be convened and will meet at least 
yearly and as required depending on the needs of the 
TSC/trial office. The TSC will provide overall oversight 
of the trial, including the practical aspects of the study, 
as well as ensuring that the study is run in a way which is 
both safe for the patients and provides appropriate feasi-
bility data to the sponsor and investigators. The TSC will 
also undertake the final assessment of feasibility. Given 
this is a pilot study, a data monitoring committee is not 
required.
Adverse events
The collection and reporting of adverse events (AEs) 
will be in accordance with the UK Policy Framework for 
Health and Social Care Research and the requirements 
of the Health Research Authority. The Investigator will 
assess the seriousness and causality (relatedness) of all AEs 
experienced by the trial participants and this assessment 
will be documented in the source data, with reference to 
the protocol.
Audit
Trials staff will be in regular contact with the site research 
team to check on progress and address any queries that 
they may have. Trials staff will check incoming ICFs and 
CRFs for compliance with the protocol, data consistency, 
missing data and timing. Sites will be sent data clarifi-
cation forms requesting missing data or clarification of 
inconsistencies or discrepancies. Sites will be requested to 
send in copies of signed ICFs and other documentation 
for in-house review for all participants providing explicit 
consent.
Qualitative substudy
Objective
To explore patient and study personnel/clinician 
thoughts/experiences regarding the RePROM trial 
processes.
Methods
Participants and study personnel/clinicians involved in 
the pilot trial will be invited to take part in the qualita-
tive substudy. Up to 40 participants (20 patients and 20 
study personnel/clinicians) will be recruited, purposively 
selected to capture those participants who experienced 
a range of outcomes and experiences during the trial 
where possible. However, recruitment will continue until 
data saturation is reached.
Semistructured interviews will be conducted by a 
member of the Centre for Patient-Reported Outcome 
Research team at the University of Birmingham according 
to a predefined topic guide, but there will be sufficient 
scope to explore novel themes where appropriate. All 
interviews will be digitally recorded, professionally tran-
scribed and the transcripts anonymised. Transcript data 
will be entered into a specialist software package (eg, 
NVivo, QSR International) to aid organisation and anal-
ysis of the data. All data will be analysed by the CI using 
conventional content analysis. Formal triangulation 
of coding and member checking will be employed to 
enhance the credibility of the analysis. Only anonymised 
quotes will be used in any arising publications or reports.
EthICs, ConfIdEntIAlIty And dIssEMInAtIon
Personal data recorded on all documents will be regarded 
as strictly confidential and will be handled and stored in 
accordance with the Data Protection Act 1998. Data trans-
ferred from the host site to the researchers (University of 
Birmingham) will be securely stored and only used for 
analysis or study monitoring relevant to the participant 
taking part in the research. The findings from the trial 
will be used to inform the design of a future, full-scale, 
RCT. Results will be submitted for publication in a peer-re-
viewed journal, presented at scientific conferences and 
disseminated to the public via lay summaries/newsletters 
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Open access
in partnership with our PAG. Study manuscripts will be 
prepared by the chief investigator and authorship will be 
determined by the trial publication policy. Intellectual 
property rights will be addressed in the Clinical Study Site 
Agreement between Sponsor and site. The full protocol is 
available on request to the corresponding author.
PAtIEnt And PublIC InvolvEMEnt
Development of the research question, outcome measures 
and study design was informed by a series of meetings 
held with the RePROM PAG, which included people with 
lived experience of CKD. The PAG reviewed all patient-
facing study documentation and considered the overall 
burden of study participation during the design process.
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